OR for achieving seropositivity in patients with hematologic malignancies vs healthy control group after 2 doses (A) and 1 dose of COVID-19 vaccine (B).
Figure 2.

OR for achieving seropositivity in patients with hematologic malignancies vs healthy control group after 2 doses (A) and 1 dose of COVID-19 vaccine (B).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal